Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

18 August 2020: Clinical Research

Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients

Ling Zhu 12ABCDEFG , Qianwei Cui 1BCEF , Ying Liu 3BCEF , Zhongwei Liu 1BCE , Yong Zhang 1BCF , Fuqiang Liu 1ACDEFG* , Junkui Wang 1ACDEFG*

DOI: 10.12659/MSM.925114

Med Sci Monit 2020; 26:e925114

Supplementary Table 2 MACE of the study patients according to risk category of always beta-blocker and statin treatment.

TotalNo therapyBeta-blocker mono-therapyStatin mono-therapyCo-therapyP value
MACE98 (15.4)40 (28.8)14 (19.7)22 (14.8)22 (7.9)
 Cardiovascular death, n (%)0 (0)0 (0)0 (0)0 (0)0 (0)
 Myocardial infarction, n (%)8 (1.3)1 (0.7)2 (2.8)1 (0.7)4 (1.4)0.531
 Ischemia-driven revascularization, n (%)* 73 (11.5)31 (22.3)9 (12.7)16 (10.7)17 (6.1)
 Progress to NYHA III or IV, n (%)17 (2.7)7 (5.0)5 (7.0)2 (1.3)3 (1.1)0.008
 Stroke, n (%)14 (2.2)6 (4.3)0 (0)5 (3.4)3 (1.1)0.071
* Included percutaneous coronary intervention and coronary artery bypass grafting.
MACE – major adverse cardiac events; NYHA – New York Heart Association.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750